Characterisation of the Novel KIR2DL3*038 Allele by Next Generation Sequencing

Affiliations

¹ Department of Experimental Research, Medical University Pleven, Pleven, Bulgaria.
² Department of Clinical Immunology, Alexandrovska University Hospital, Medical University, Sofia, Sofia, Bulgaria.
³ Department of Clinical Hematology, Saint Marina University Hospital, Medical University Varna, Varna, Bulgaria.

Velizar Shivarov et al. HLA. 2025 Jun.

. 2025 Jun;105(6):e70297.

doi: 10.1111/tan.70297.

¹ Department of Experimental Research, Medical University Pleven, Pleven, Bulgaria.
² Department of Clinical Immunology, Alexandrovska University Hospital, Medical University, Sofia, Sofia, Bulgaria.
³ Department of Clinical Hematology, Saint Marina University Hospital, Medical University Varna, Varna, Bulgaria.

Abstract

The novel KIR2DL3*038 allele was detected by Next Generation Sequencing.

Keywords: KIR2DL3; NGS; novel allele; the Bulgarian population.

1. J. Trowsdale, “Genetic and Functional Relationships Between MHC and NK Receptor Genes,” Immunity 15, no. 3 (2001): 363–374.
1. M. Falco, L. Moretta, A. Moretta, and C. Bottino, “KIR and KIR Ligand Polymorphism: A New Area for Clinical Applications?,” Tissue Antigens 82, no. 6 (2013): 363–373.
1. P. Parham and L. A. Guethlein, “Genetics of Natural Killer Cells in Human Health, Disease, and Survival,” Annual Review of Immunology 36 (2018): 519–548.
1. G. Maccari, J. Robinson, J. A. Hammond, and S. G. E. Marsh, “The IPD Project: A Centralised Resource for the Study of Polymorphism in Genes of the Immune System,” Immunogenetics 72, no. 1–2 (2020): 49–55.
1. S. G. E. Marsh, P. Parham, B. Dupont, et al., “Killer‐Cell Immunoglobulin‐Like Receptor (KIR) Nomenclature Report, 2002,” Tissue Antigens 62, no. 1 (2003): 79–86.